top of page

News of Note - February 27, 2023


Monday, February 27, 2023


Not sure how I feel about Pfizer taking out Seagen, though the groundwork was clearly laid for it last year (multiple ADC spinouts/ cullings, deals closed, immaculate balance sheet, etc.).. Bourla will have some “immediately accretive” gymnastics to do here, if this happens..


  • ADCs -> dropped HER2, Pyxis spin, Pyxis additional

  • ARRY -> talk of spinning them out

  • Deals -> all closed

  • Balance sheet -> LOL

Why now:

  • Besides LOE window, competition in key assets is a bigger deal than is talked about, looking at you palbo, enza, tofa..

  • Now, this would run a bit ahead of the multiple they mentioned at the JPM Healthcare confab (2.6x) but maybe they’ve got much higher revenue projections for Seagen?

  • Not to be lost in this is that, of course, Seagen has an ARRY asset onboard X) haHA!

  • As always, other bits of the Pfizer story to consider beyond net cash and fcf..

  • CentreOne reports on its own now (wink/nod)

  • ViiV stake, 11.7%

  • Haleon stake, 32%

  • $1bn + of various equity (they likely don't sell these)

This wouldn't end deals in the least, firepower galore; though it is a relatively large swing.. I don't *hate* it completely..


Br. -john






AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults with Moderate to Severe Crohn's Disease

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. -CapIQ


Blueprint Medicines

Presents Registrational Data from PIONEER Trial of AYVAKIT® (avapritinib) in Patients with Indolent Systemic Mastocytosis at 2023 AAAAI Annual Meeting

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. -CapIQ


Berkshire Hathaway

Annual Report

Berkshire Hathaway Inc., through its subsidiaries, engages in the insurance, freight rail transportation, and utility businesses worldwide. -CapIQ



Darolutamide receives approval for additional prostate cancer indication in Japan

  • Darolutamide approved for metastatic prostate cancer as well as non-metastatic castration-resistant prostate cancer

  • New approval is based on data from the pivotal Phase III ARASENS trial

  • cc: BAYN GY Bayer

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, other European countries, North America, and internationally.



Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases.



Pfizer in Talks to Acquire Seagen in Deal Likely Valued at More Than $30 Billion

  • Potential deal would help the drug company add to its lineup of cancer treatments

Have we found the genetic signature for vasovagal syncope?

GSK Spinoff Haleon Explores Potential $600 Million Sale of ChapStick Brand

How to pull carbon dioxide out of seawater

bottom of page